AI assistant
Celldex Therapeutics, Inc. — Director's Dealing 2021
Aug 13, 2021
31801_dirs_2021-08-13_1ad84092-a45a-463c-981b-ed1a89a119b7.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Celldex Therapeutics, Inc. (CLDX)
CIK: 0000744218
Period of Report: 2021-08-11
Reporting Person: Heath-Chiozzi Margo (SVP of Regulatory Affairs)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-08-11 | Common Stock | M | 10000 | $9.0165 | Acquired | 11247 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-08-11 | Incentive Stock Option | $9.0165 | M | 10000 | Disposed | 2028-06-13 | Common Stock (10000) | Direct |
Footnotes
F1: Includes 247 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan. On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
F2: This option was previously reported as covering 275,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split.
F3: 25% vested on June 13, 2019 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters